Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 1
2007 2
2008 3
2009 3
2010 1
2011 5
2012 5
2013 6
2014 6
2015 8
2016 2
2017 4
2018 5
2019 11
2020 9
2021 11
2022 7
2023 7

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
Mathieu LN, Larkins E, Akinboro O, Roy P, Amatya AK, Fiero MH, Mishra-Kalyani PS, Helms WS, Myers CE, Skinner AM, Aungst S, Jin R, Zhao H, Xia H, Zirkelbach JF, Bi Y, Li Y, Liu J, Grimstein M, Zhang X, Woods S, Reece K, Abukhdeir AM, Ghosh S, Philip R, Tang S, Goldberg KB, Pazdur R, Beaver JA, Singh H. Mathieu LN, et al. Among authors: amatya ak. Clin Cancer Res. 2022 Jan 15;28(2):249-254. doi: 10.1158/1078-0432.CCR-21-1566. Epub 2021 Aug 3. Clin Cancer Res. 2022. PMID: 34344795 Review.
FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer.
Shah M, Osgood CL, Amatya AK, Fiero MH, Pierce WF, Nair A, Herz J, Robertson KJ, Mixter BD, Tang S, Pazdur R, Beaver JA, Amiri-Kordestani L. Shah M, et al. Among authors: amatya ak. Clin Cancer Res. 2022 Dec 15;28(24):5249-5253. doi: 10.1158/1078-0432.CCR-22-1110. Clin Cancer Res. 2022. PMID: 35925043 Clinical Trial.
Why study global health?
Amatya A, Basel P. Amatya A, et al. Kathmandu Univ Med J (KUMJ). 2014 Apr-Jun;12(46):87-8. doi: 10.3126/kumj.v12i2.13650. Kathmandu Univ Med J (KUMJ). 2014. PMID: 25552208 No abstract available.
Post-approval drug safety surveillance.
Gibbons RD, Amatya AK, Brown CH, Hur K, Marcus SM, Bhaumik DK, Mann JJ. Gibbons RD, et al. Among authors: amatya ak. Annu Rev Public Health. 2010;31:419-37. doi: 10.1146/annurev.publhealth.012809.103649. Annu Rev Public Health. 2010. PMID: 20070192 Free PMC article. Review.
Using simulations to advance clinical reasoning.
Reinhardt AC, León TG, DeBlieck C, Amatya A. Reinhardt AC, et al. Among authors: amatya a. Appl Nurs Res. 2019 Jun;47:63-70. doi: 10.1016/j.apnr.2019.05.005. Epub 2019 May 8. Appl Nurs Res. 2019. PMID: 31113550 No abstract available.
Bayesian Methods in Human Drug and Biological Products Development in CDER and CBER.
Ionan AC, Clark J, Travis J, Amatya A, Scott J, Smith JP, Chattopadhyay S, Salerno MJ, Rothmann M. Ionan AC, et al. Among authors: amatya a. Ther Innov Regul Sci. 2023 May;57(3):436-444. doi: 10.1007/s43441-022-00483-0. Epub 2022 Dec 2. Ther Innov Regul Sci. 2023. PMID: 36459346 Free PMC article. Review.
Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples.
Amatya AK, Fiero MH, Bloomquist EW, Sinha AK, Lemery SJ, Singh H, Ibrahim A, Donoghue M, Fashoyin-Aje LA, de Claro RA, Gormley NJ, Amiri-Kordestani L, Sridhara R, Theoret MR, Kluetz PG, Pazdur R, Beaver JA, Tang S. Amatya AK, et al. Clin Cancer Res. 2021 Nov 1;27(21):5753-5756. doi: 10.1158/1078-0432.CCR-20-4912. Epub 2021 Jun 11. Clin Cancer Res. 2021. PMID: 34117032 Free PMC article. Review.
89 results